Incidental Acinic Cell Carcinoma of the Parotid Gland Discordant on 123I-MIBG, 111In-Octreotide, and 18F-FDG PET/CT in a Patient With Neuroendocrine Tumor of the Cecum.

Abstract

A 61-year-old woman diagnosed with a metastatic well-differentiated neuroendocrine tumor of the cecum was referred for radioisotope therapy. Although her metastatic neuroendocrine tumor was positive on both (123)I-MIBG and (111)In-octreotide, there was a left parotid mass that was octreotide avid but MIBG negative. Further investigation also showed discordance on (18)F-FDG PET/CT and excision of the mass revealed an incidental acinic cell carcinoma of the parotid gland. Somatostatin analog imaging and PRRT (peptide receptor radionuclide therapy) may have a role in the management of acinic cell carcinoma.

• Authors: William Makis, Karey McCann, Alexander J B McEwan
• Journal: Clinical nuclear medicine (Clin Nucl Med) Vol. 40 Issue 8 Pg. 676-8 (Aug 2015) ISSN: 1536-0229 [Electronic] United States
• PMID: 25674880 (Publication Type: Case Reports, Journal Article)

Chemical References

• Radiopharmaceuticals
• indium-111-octreotide
• Fluorodeoxyglucose F18
• 3-Iodobenzylguanidine
• Octreotide

Topics

• 3-Iodobenzylguanidine
• Carcinoma, Acinar Cell (diagnostic imaging)
• Cecal Neoplasms (diagnostic imaging, pathology)
• Female
• Fluorodeoxyglucose F18
• Humans
• Incidental Findings
• Middle Aged
• Multimodal Imaging
• Neoplasm Metastasis
• Neuroendocrine Tumors (diagnostic imaging, pathology)
• Octreotide (analogs & derivatives)
• Parotid Neoplasms (diagnostic imaging)
• Positron-Emission Tomography
• Radiopharmaceuticals
• Tomography, X-Ray Computed